Fig. 1: Anti-leukemia activity of AAV-CD19BiTE in vivo. | Blood Cancer Journal

Fig. 1: Anti-leukemia activity of AAV-CD19BiTE in vivo.

From: In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies

Fig. 1

A NCG mice were intravenously injected with 2 × 106 NALM-6 cells, followed by infused with PBMC, PBMC+AAV-GFP (AAV-GFP), and PBMC+AAV-CD19BiTE (AAV-CD19BiTE), respectively. Bioluminescent images of differently treated mice over time (n = 5). B The weight changes of differently treated mice. C The comparison of tumor burdens on day 19 following NALM-6 cells injection. P values were calculated using a one-way ANOVA test with post-hoc analysis. D Kaplan–Meier analysis was performed to evaluate the survival differences among different treatment groups.

Back to article page